A new drug combination for HER2-positive advanced stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two targeted drugs (disitamab vedotin and sintilimab) along with radiation for HER2-positive stomach cancer that has stopped responding to standard treatments. The goal is to see if this combo can shrink tumors and help you live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced stomach cancer that tested positive for HER2 (a protein that helps cancer grow).
- You have tried and failed or couldn't tolerate at least two standard treatments.
- Your liver is working well enough (Child-Pugh class A).
- You have at least one tumor that can be measured on a scan, and at least two spots that can get radiation.
- If you have hepatitis B, it must be well controlled with medication.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs for stomach cancer that has spread and shows a specific protein (HER2). The goal is to see if the combination helps patients who haven't had treatment for advanced disease.
This trial tests a new combination of drugs (RC48, sintilimab, and SOX chemotherapy) for people with stomach or gastroesophageal junction cancer that cannot be removed by surgery, has not been treated before, and has a specific HER2 score (1+ or 2+). The goal is to shrink the tumor enough to possibly allow surgical removal.
This trial tests two drugs, disitamab vedotin and trastuzumab, for people with HER2-positive stomach or gastroesophageal junction cancer that has spread or come back after at least one prior treatment. The goal is to see if this combination can help shrink tumors.
This trial tests a combination of three drugs—disitamab vedotin, tunlametinib, and a PD-1 antibody—for people with advanced stomach cancer that has HER2 (a protein that helps cancer grow). The goal is to see if this combo can shrink tumors or slow the cancer, and whether it's safe.
This study tests a new combination of three drugs (disitamab vedotin, tislelizumab, and chemotherapy) compared to two of them (tislelizumab plus chemotherapy) for people with advanced stomach or gastroesophageal junction cancer that has low levels of a protein called HER2. It aims to see if adding the third drug helps shrink or control the cancer better.
This trial tests a new approach for stomach cancer that has spread to nearby tissues but not to other organs. You would get a short course of radiation, followed by a combination of targeted therapy (Disitamab Vedotin), chemotherapy (S-1), and immunotherapy (Sintilimab) before surgery to shrink the tumor and improve outcomes.
Hear when a new HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.